TC BIOPHARM (HOLDINGS) PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.14 USD | -1.72% |
|
+3.64% | -64.04% |
| May. 15 | European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading | MT |
| May. 15 | TC Biopharm Plc Announces Launch of Compassionate Use Program for TCB008 | CI |
| Sales 2022 | 3.84M 4.91M | Sales 2023 | - | Capitalization | 1.35M 1.73M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -1.28M | Net income 2023 | -5M -6.38M | EV / Sales 2022 | 0.26 x |
| Net cash position 2022 | 2.01M 2.57M | Net cash position 2023 | 661K 844K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.57
x | P/E ratio 2023 |
-0.13
x | Employees | 41 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.24% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -1.72% | ||
| 1 week | +3.64% | ||
| Current month | -20.28% | ||
| 1 month | -25.49% | ||
| 3 months | -10.24% | ||
| 6 months | -86.43% | ||
| Current year | -64.04% |
1 week
1.11
1.20
1 month
1.063.00
Current year
0.853.35
1 year
0.8519.60
3 years
0.853 500.00
5 years
0.853 500.00
10 years
0.853 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Bryan Kobel
CEO | Chief Executive Officer | 44 | 21-05-31 |
Martin Thorp
DFI | Director of Finance/CFO | 72 | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Bonyhadi
BRD | Director/Board Member | 70 | 22-02-21 |
Martin Thorp
DFI | Director of Finance/CFO | 72 | 14-12-31 |
Arlene Morris
CHM | Chairman | 72 | 22-02-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 1.14 | +0.88% | 127,925 |
| 24-05-24 | 1.13 | -0.88% | 126,538 |
| 24-05-23 | 1.14 | -1.72% | 98,898 |
| 24-05-22 | 1.16 | 0.00% | 175,108 |
| 24-05-21 | 1.16 | +5.45% | 558,067 |
End-of-day quote Nasdaq, May 22, 2024
More quotes
TC BioPharm Limited is a clinical-stage cell therapy company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. Its platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. Its pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications. The Companyâs therapies are focused on leveraging the inherent biological capabilities of GDT cells together with an integrated cell engineering approach.
| 1st Jan change | Capi. | |
|---|---|---|
| -64.04% | 3.61M | |
| +54.05% | 63.85B | |
| -2.02% | 41.83B | |
| +40.01% | 40.47B | |
| -10.22% | 27.17B | |
| +13.42% | 26.52B | |
| -21.60% | 18.69B | |
| +2.89% | 12.73B | |
| +22.40% | 12.11B | |
| +27.49% | 12.07B |
- Stock Market
- Equities
- TCBP Stock
